{"id":"W4408563004","doi":"10.1016/j.esmoop.2025.104506","title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck; Pfizer","keywords":"Javelin; Urothelial carcinoma; Avelumab; Medicine; Oncology; Carcinoma; Term (time); Urology; Internal medicine; Bladder cancer; Immunotherapy; Cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002680116,0.0003948057,0.0009866209,0.0001808326,0.0002085842,0.0006950275,0.0003994723,0.0005158399,0.001233131],"category_scores_gemma":[0.00179772,0.0001729894,0.001507621,0.0003241366,0.0003416284,0.0004704195,0.0003655658,0.001403668,0.0001495558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004689638,"about_ca_system_score_gemma":0.0005047717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006194359,"about_ca_topic_score_gemma":0.002044935,"domain_scores_codex":[0.9993755,0.0004116886,0.00003870923,0.00005926549,0.00004824627,0.0000666186],"domain_scores_gemma":[0.998711,0.0003163664,0.0003860659,0.00008405907,0.00005362471,0.0004489056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8548577,0.004123007,0.04865327,0.001601939,0.006315235,0.0001642506,0.0001930703,0.00212953,0.006410829,0.000265285,0.004415123,0.07087068],"study_design_scores_gemma":[0.5302355,0.1676513,0.2751937,0.0006054292,0.01207376,0.0005958888,0.0002032099,0.003081627,0.001701206,0.0006913137,0.007877035,0.00008999511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864797,0.01111033,0.0001532847,0.0004462122,0.00008677617,0.0001566883,0.0007395746,0.00001341633,0.0008140731],"genre_scores_gemma":[0.9922678,0.004126086,0.0003052874,0.0005788806,0.0001684477,0.0002878286,0.001701616,0.000008088783,0.0005561047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002680116,"threshold_uncertainty_score":0.01417398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03674774194139571,"score_gpt":0.3389780122487699,"score_spread":0.3022302703073743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}